Literature DB >> 11229475

Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus.

B H Hahn1, R R Singh, W K Wong, B P Tsao, K Bulpitt, F M Ebling.   

Abstract

OBJECTIVE: To test the hypothesis that an artificial peptide, based on an algorithm describing T cell stimulatory sequences from the VH regions of murine IgG antibodies to DNA, is an effective tolerogen in vivo in the (NZB/NZW)F1 (BWF1) mouse model of systemic lupus erythematosus.
METHODS: Using proliferative T cell responses to 439 Ig peptides, an algorithm was constructed that describes the amino acid sequences likely to stimulate BWF1 T cells. Stimulatory (pConsensus [pCONS]) or nonstimulatory (pNegative [pNEG]) peptides were synthesized. Groups of 10-week-old (healthy) or 20-week-old (diseased) BWF1 mice received monthly intravenous injections of 1,000 microg of peptide or saline. Ex vivo splenic T cell responses and in vivo clinical effects were measured.
RESULTS: Tolerance was induced by pCONS, but not by pNEG, with respect to ex vivo T cell proliferation and T cell help for antibodies to DNA. T cell help for IgG anti-DNA was impaired not only after T cell stimulation by pCONS but also after stimulation by some peptides from nucleosomal and Ro antigens. Treatment with pCONS significantly delayed the onset of nephritis and inhibited increases in the plasma levels of total IgG, IgG antibodies to DNA, nucleosome, cardiolipin, interferon-gamma, and interleukin-4. In contrast, antibody responses to an exogenous antigen were not impaired. Survival was significantly prolonged in both healthy and diseased mice treated with pCONS.
CONCLUSION: Induction of immune tolerance in response to treatment with pCONS in autoreactive T cell helper populations is highly effective in delaying the appearance of multiple autoantibodies, cytokine increases, and nephritis in BWF1 mice, and dramatically prolongs survival. A striking effect is the ability of the peptide to tolerize T cell help for anti-DNA that is induced by multiple, structurally unrelated self antigens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229475     DOI: 10.1002/1529-0131(200102)44:2<432::AID-ANR62>3.0.CO;2-S

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  30 in total

Review 1.  A model for lupus brain disease.

Authors:  Betty Diamond; Bruce T Volpe
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 2.  SLE: translating lessons from model systems to human disease.

Authors:  Ram Raj Singh
Journal:  Trends Immunol       Date:  2005-09-09       Impact factor: 16.687

3.  Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice.

Authors:  Elaine V Lourenço; Claudio Procaccini; Francesca Ferrera; Noriko Iikuni; Ram P Singh; Gilberto Filaci; Giuseppe Matarese; Fu-Dong Shi; Ernest Brahn; Bevra H Hahn; Antonio La Cava
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

4.  T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus.

Authors:  G Riemekasten; C Weiss; S Schneider; A Thiel; A Bruns; F Schumann; S Bläss; G-R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 5.  Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice.

Authors:  Brian J Skaggs; Ram Pyare Singh; Bevra H Hahn
Journal:  Hum Immunol       Date:  2008-09-24       Impact factor: 2.850

Review 6.  Inhibitory CD8+ T cells in autoimmune disease.

Authors:  Masakatsu Suzuki; Christine Konya; Jörg J Goronzy; Cornelia M Weyand
Journal:  Hum Immunol       Date:  2008-09-21       Impact factor: 2.850

Review 7.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

8.  Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.

Authors:  N Mauermann; Z Sthoeger; H Zinger; E Mozes
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 9.  Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

Authors:  Fanny Monneaux; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

10.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.